Greg Slabodkin

The CDMO plans to allocate most of offering proceeds toward its PolyPeptide Group acquisition, with the remaining funds slated for Bio Campus II investment.

Bioreactor automation and control systems grow to 38.6% adoption or planned implementation, finds 2026 annual report and survey by BioPlan Associates.

The drugmakers pledged to invest $19.6 billion collectively in U.S. manufacturing and provide discounts on select medicines in exchange for tariff exemptions.

Five teams will create automated platforms capable of producing RNA-based genetic medicines and performing quality control testing at or near the point of care.

The company is investing approximately $108 million in a new drug product facility in Vancouver, Canada, and $100 million to modernize its Indiana API manufacturing site.

Recent site upgrades, acquisitions, and new partnerships demonstrate a shift from cost-driven outsourcing to integrated, locally anchored models, says the firm.

Under the Bio100 initiative, the company will invest about $300 million in a new drug substance facility in Slovenia to expand its biosimilar manufacturing capacity.

Customers of outsourced services are putting greater emphasis on reliability, execution, and cost competitiveness, according to consulting firm McKinsey & Company.

The biopharma company continues to scale its production capabilities to support a growing portfolio of pharmaceuticals, vaccines, and biologics.

Under a deal worth $120 million over 10 years, Ori's IRO platform will be integrated into an undisclosed company's commercial cell therapy production process.